Table 2 The pooled proportions of outcomes for lymphoma with CD19 CAR-T cell therapy
From: Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
Outcomes | No. of studies | Patients (n/N) | Pooled proportion (%) | 95% CI | Heterogeneity | Publication bias | |
|---|---|---|---|---|---|---|---|
I2(%) | p-value | p-value | |||||
All-cause mortality | 6 | 130/683 | 17.8 | [0.057; 0.299] | 94.56 | < 0.01 | < 0.05 |
CV events | 10 | 275/1435 | 17.8 | [0.116; 0.240] | 95.57 | < 0.01 | < 0.05 |
Arrhythmias | 6 | 69/547 | 11.5 | [0.089; 0.142] | 37.7 | = 0.15 | > 0.05 |
HF | 6 | 36/990 | 3% | [0.012; 0.048] | 62 | = 0.02 | > 0.05 |
Cardiomyopathy | 3 | 6/505 | 0.6 | [0.000; 0.012] | 36.53 | = 0.21 | > 0.05 |
Cardiac arrest | 3 | 6/441 | 1.3 | [0.003; 0.024] | 0 | = 0.92 | > 0.05 |
Other CV events | 3 | 7/203 | 2.5 | [0.004; 0.047] | 3 | = 0.36 | > 0.05 |
Hypotension | 6 | 366/639 | 52.8 | [0.239; 0.816] | 99.45 | < 0.01 | > 0.05 |